Date: 2016-05-10
Type of information: Development agreement
Compound: mRNA vaccines and therapeutics
Company: Bayer Healthcare (Germany) Biontech (Germany)
Therapeutic area: Veterinary medicine
Type agreement: development
Action mechanism:
Disease:
Details: * On May 10, 2016, Bayer and BioNTech, an immunotherapy company headquartered in Mainz, have entered into an agreement to develop novel, first-in-class mRNA vaccines and therapeutics specifically for Animal Health applications. BioNTech will contribute its proprietary mRNA technology platform, formulation development capabilities, immunology expertise and intellectual property, while Bayer’s Animal Health unit will provide its development expertise and disease know-how. This is the first partnership of its kind making a substantial investment in mRNA therapeutics specifically for Animal Health applications. Through the agreement, Bayer secures exclusive rights to use BioNTech’s proprietary mRNA technology and intellectual property for development of mRNA vaccines for Animal Health applications, while BioNTech gains exclusive access to Bayer’s extensive expertise and knowledge in veterinary medicine. Newly created know-how from the collaboration beyond Animal Health applications, will benefit BioNTech’s extensive human health program. The agreement is backed by an investment by the Bayer Lifescience Center (BLSC), which operates as a novel strategic innovation unit in Bayer, directly reporting to Bayer´s Board of Management. The BLSC has the mission to uncover, encourage and unlock fundamental scientific and medical breakthroughs more rapidly by enabling innovative partnerships with entrepreneurial best-in-class biotechnology companies. The terms of the agreement were not disclosed.
Financial terms:
Latest news:
